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Abstract
Rationale: Hypersensitivity Pneumonitis (HP) is an interstitial lung disease (ILD) characterized
by inflammation and/or fibrosis in response to an inhalational exposure.
Objective: To determine the value of bronchoalveolar lavage (BAL) fluid lymphocyte cellular
analysis in the detection of HP among patients with newly detected ILD.
Methods: This systematic review was undertaken in the context of development of an
American Thoracic Society (ATS), Japanese Respiratory Society (JRS), and Asociación
Latinoamericana del Tórax (ALAT) clinical practice guideline. The clinical question was, “should
patients with newly detected ILD undergo BAL fluid lymphocyte analysis to diagnose HP?”
Medline, Embase, and grey literature were searched through October 2019. Studies that
reported the percentage of BAL fluid lymphocytes for various ILDs were selected for inclusion.
Meta-analyses compared the mean percentage of BAL fluid lymphocytes among patients with
HP to that among patients with Idiopathic Pulmonary Fibrosis (IPF) or sarcoidosis. The
sensitivity and specificity by which various percentages of BAL fluid lymphocytes distinguish HP
from IPF and sarcoidosis were also evaluated.
Results: Eighty-four articles were selected. No randomized trials or observational studies were
identified that compared BAL fluid lymphocyte analysis to no BAL fluid lymphocyte analysis in
patients with ILD. Included studies were case series describing BAL fluid cell differentials in
patients with various ILDs. The percentage of BAL fluid lymphocytes was significantly higher in
both fibrotic and nonfibrotic HP compared to IPF. Similarly, the percentage of BAL fluid
lymphocytes was significantly higher in both fibrotic and nonfibrotic HP compared to
sarcoidosis. A threshold of 20% BAL fluid lymphocytes distinguished fibrotic HP from IPF with a
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sensitivity and specificity of 69% and 61% respectively, and nonfibrotic HP from IPF with a
sensitivity and specificity of 95% and 61% respectively. It distinguished fibrotic HP from
sarcoidosis with a sensitivity and specificity of 69% and 26% respectively, and nonfibrotic HP
from sarcoidosis with a sensitivity and specificity of 95% and 26% respectively.
Conclusion: The percentage of BAL fluid lymphocytes is higher in HP than IPF or sarcoidosis.
However, a threshold that distinguishes HP from IPF or sarcoidosis with both high sensitivity
and high specificity was not identified.

Abstract Word Count: 348
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Hypersensitivity Pneumonitis (HP) is an interstitial lung disease (ILD) characterized by immunemediated inflammation with or without fibrosis in response to inhalational exposure to various
inciting agents [1]. The incidence of HP varies with geographic location. In the United States,
the one-year cumulative incidence of HP ranges from 1.28 to 1.94 cases per 100,000 persons
[2]. More than half of these cases are related to chronic HP [2].
Various definitions, classifications, and diagnostic criteria have been proposed for HP
[3,4,5,6,7], but they have failed to gain widespread acceptance. A new definition and updated
classification and diagnostic criteria for HP are needed to standardize clinical care and facilitate
research [8]. BAL lymphocytosis has been proposed as a diagnostic criterion for HP [3,4,9].
However, the ability of BAL fluid lymphocyte analysis to distinguish the nonfibrotic and fibrotic
types of HP from various ILDs is unknown, as is the optimal threshold BAL lymphocyte count to
diagnose HP [10-12].
This systematic review was performed in the context of development of an American
Thoracic Society (ATS), Japanese Respiratory Society (JRS), and Asociación Latinoamericana del
Tórax (ALAT) guideline on the diagnosis of HP [13]. The goals of the systematic review were to
answer the question, “should patients with newly detected ILD in a chest radiograph or CT scan
of the chest, with or without a history of exposure capable of causing HP, undergo BAL fluid
lymphocyte analysis to diagnosis HP” and to identify a threshold BAL lymphocyte count that
distinguishes HP from other ILDs.
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Methods

This review was performed in accordance with the standards described in the Cochrane
Handbook of Systematic Reviews of Diagnostic Test Accuracy [14]. The systematic review was
not registered because it was performed in the context of guideline development rather than
de novo and was initiated prior to the requirement that such systematic reviews be registered.

Research Questions
The population, intervention, comparator, outcome (PICO) format was used to develop the
question - “should patients with newly detected ILD in a chest radiograph or CT scan of the
chest, with or without a history of exposure capable of causing HP, undergo BAL fluid
lymphocyte cellular analysis to diagnosis HP?” The population was adult patients who have
newly detected ILD, the intervention was BAL fluid lymphocyte cellular analysis, the comparator
was no BAL fluid lymphocyte cellular analysis, and the outcomes included diagnostic test
characteristics. An secondary question was also posed, “is there a threshold percentage of BAL
fluid lymphocytes that is diagnostic of HP?”

Literature Search
Potentially relevant systematic reviews were initially sought in the Cochrane Library and
MEDLINE but none were identified. A sensitive search strategy was therefore developed and
used to search for potentially relevant studies in MEDLINE, EMBASE, and the grey literature
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(Table E1). An initial search encompassed January 1946 through April 2019, which was updated
to include through October 2019.

Study Selection
Two reviewers independently reviewed all studies for inclusion and exclusion criteria.
Disagreements were resolved by discussion. The study selection process was established a
priori. (Table E2). Randomized controlled trials comparing BAL fluid lymphocyte cellular analysis
to no BAL fluid lymphocyte cellular analysis in patients with newly detected ILD were initially
sought. If none were found, observational studies comparing BAL fluid lymphocyte cellular
analysis to no BAL fluid lymphocyte cellular analysis in patients with ILD were sought. If none
were found, case series that enrolled patients with ILD who underwent BAL fluid lymphocyte
cellular analysis were sought, including studies that reported the BAL fluid lymphocyte count or
proportion in a given type of ILD and studies that compared the BAL fluid lymphocyte count or
proportion in different types of ILD. Case series with fewer than 20 patients and non-English
language studies were excluded.

Data Extraction
A standardized data form was developed for data extraction from the selected studies. Data
were extracted independently by two investigators. Extracted information included the author,
date, study location, study design, diagnostic criteria for various ILDs, number of participants,
chest radiograph and CT scan findings, details of intervention, details of the comparator, and
outcomes. Extracted data were reviewed and confirmed by a third reviewer.
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Data Synthesis
To determine whether BAL can be used to distinguish HP from other ILDs, meta-analyses were
performed using studies in which the mean percentage of BAL fluid lymphocytes in patients
with HP was compared to that in patients with other ILDs .The meta-analyses utilized a random
effects model in the Cochrane Collaboration Review Manager, version 5.3. The mean difference
(MD) and accompanying 95% confidence interval (CI) was the summary estimate. Subgroup
analyses were performed for patients with fibrotic (chronic) HP, nonfibrotic (acute or subacute)
HP, and non-specified HP.
Statistical heterogeneity was measured using the I2 test; an I2 ≥75%, 50-75%, and 2550% was considered severe, moderate, and mild, respectively. When heterogeneity was
encountered, sensitivity analyses were performed to identify the contributing studies and then
reasons for the heterogeneity were sought. The sensitivity analyses consisted of removing from
the meta-analysis studies whose results appeared to be different from most studies and then
reassessing the I2 statistic. If the I2 statistic improved, reviewing the full text of the removed
studies to determine if those studies were similar to each other and different from the others in
a way that might explain the different results, such as enrolling a different population,
performing the BAL differently, or measuring the lymphocyte count differently. If no cause was
found, outliers were eliminated. Outliers were defined as studies whose confidence interval did
not overlap the confidence interval of the pooled estimate. The estimates after elimination of
the outliers are reported here but results both before and after the elimination of outliers are
shown in the figures.
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To identify a threshold that distinguishes HP from other ILDs, we had hoped to find
multiple studies conducted at various thresholds that could be pooled, or to perform an
individual patient data meta-analysis to evaluate various thresholds. However, the former did
not exist, and the latter proved infeasible. Therefore, we assumed the percentage of BAL fluid
lymphocytes is normally distributed and created two normal distributions, one representing a
disease-positive population (i.e., patients with HP) and the other representing a diseasenegative population (i.e., patients with other ILDs). As the sample size increases, confidence in
the normal distribution increases; therefore, to obtain larger sample size, similar subgroups
were combined. For example, to obtain larger sample of nonfibrotic HP patients, we combined
all non-fibrotic HP patients irrespective of their comparator. Studies previously identified as
outliers were not used to calculate the mean of the normal distribution. IBM SPSS Statistic 24
software was used to obtain the normal distributions based on mean and standard deviation.
For BAL lymphocyte counts ranging from 0% to 100%, true-positive, false-negative, truenegative, and false-positive rates were determined at 5% increments, and a summary receiver
operator curve was constructed using Microsoft Excel. The area under the curve was calculated.

Quality of Evidence
Quality of evidence indicates confidence in the accuracy of the estimated effects. It was
assessed using the Grading of Recommendations, Assessment, Development, and Evaluation
(GRADE) approach. The GRADE approach makes a baseline assessment based upon study
design: randomized trials are high-quality evidence, controlled observational studies are lowquality evidence, and case series are very low-quality evidence. After making a baseline
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assumption, five domains are assessed: Risk of bias (internal validity), indirectness (external
validity), inconsistency of estimates across the studies (heterogeneity), imprecision (wide CIs),
and publication bias. If any of the domains were present, the quality of evidence is
downgraded. The quality of evidence can also be upgraded if there is a large magnitude of
effect, dose-response gradient, or likely confounders would bias the study toward the opposite
result.
To assess the risk of bias domain, the Newcastle-Ottawa scale and the Quadas-2 tool
were modified to be applicable for case series. Potential risks of bias included not consecutively
enrolling patients (i.e., selection bias), patients leaving the study (i.e., attrition bias), and not
analyzing or reporting data collected (i.e., reporting bias). To assess for potential publication
bias, funnel plots were created using RevMan (Figure E1).

Evidence Profile
Evidence profiles were developed that summarize the estimated effects and judgments made
to rate the quality of evidence. During the development of the clinical practice guideline, the
evidence profiles were presented to the guideline panel to inform their recommendations.

Results

The literature search identified 1,500 articles, of which 340 articles underwent full-text review
(Figure 1). There were no randomized trials or observational studies comparing BAL fluid
lymphocyte cellular analysis to no BAL fluid lymphocyte cellular analysis in patients with ILD.
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Therefore, 84 case series were selected that reported BAL fluid lymphocyte counts for HP and
other ILDs [15-98] (Table E3). The series ranged in size from 19 to 618 patients. All of the series
were retrospective, enrolled patients with HP, and reported BAL lymphocyte count
retrospectively. The series used different criteria to diagnose HP. All used clinical and
radiographic criteria, but some added serological criteria and/or BAL criteria.

Hypersensitivity Pneumonitis versus Idiopathic Pulmonary Fibrosis
Forty-nine studies compared the percentage of BAL fluid lymphocytes in patients with HP to
that in patients with IPF [15-63]: 15 studies enrolled patients with nonfibrotic HP [30-44], 15
studies enrolled patients with fibrotic HP [15-29], and 19 studies did not specify the type of HP
[45-63]. An initial meta-analysis revealed severe heterogeneity and the cause of the
heterogeneity could not be determined; therefore, outliers were removed [27-29,39-44,60-63].
For all studies, the mean percentage of BAL fluid lymphocytes was significantly higher for HP
than IPF (MD 30.38%, 95% CI 26.78-33.99%). In subgroup analyses, the mean difference in the
percentage of BAL fluid lymphocytes between nonfibrotic HP and IPF was 34.21% (95% CI
28.66-39.76%), The mean difference in the percentage of BAL fluid lymphocytes between
fibrotic HP and IPF was 20.81% (95% CI 14.45-27.17%) (Figure 2).
The quality of evidence was judged very low because the body of evidence consisted of
case series with risk of bias due to non-consecutive enrollment of subjects and inconsistent
results across studies (Table 1).
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Hypersensitivity Pneumonitis versus Sarcoidosis
Seventy-one studies compared the percentage of BAL fluid lymphocytes in patients with HP to
that in patients with sarcoidosis [15,18-19,21-23,29-30,32-33,36-37,39-54,57-60,62-98]: 25
studies enrolled patients with nonfibrotic HP [30-33,36-37,40-44,64-77], 17 studies enrolled
patients with fibrotic HP [15,18-19,21-23,29,75,78-84,96,98], and 29 studies did not specify the
type of HP [39,45-54,57-60,62-63,85-95,97]. An initial meta-analysis revealed severe
heterogeneity and the cause of the heterogeneity could not be determined; therefore, outliers
were removed [21,33,40-43,51,62-63,65,71-72,85,88,91,94,97]. For all studies, the mean
percentage of BAL fluid lymphocytes was significantly higher for HP than sarcoidosis (MD
19.32%, 95% CI 17.28-21.36%). In subgroup analyses, the mean difference in the percentage of
BAL fluid lymphocytes between nonfibrotic HP and sarcoidosis was 24.58% (95% CI 22.0727.10%). The mean difference in the percentage of BAL fluid lymphocytes between fibrotic HP
and sarcoidosis was 15.68% (95% CI 11.25-20.10%) (Figure 3).
The quality of evidence was judged very low because the body of evidence consisted of
case series with risk of bias due to non-consecutive enrollment of subjects and inconsistent
results across studies (Table 2).

Threshold Percentage BAL Fluid Lymphocytes
Sensitivity and specificity were determined at different thresholds of percent BAL fluid
lymphocytes and summary receiver operating curves were constructed. To distinguish fibrotic
HP from IPF, BAL fluid lymphocyte thresholds of 20%, 30%, and 40% yielded sensitivities of 69%,
55%, and 41%, respectively, and specificities of 61%, 80%, and 93% respectively, with an area
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under the curve of 0.54 (95% CI 0.51-0.58). To distinguish nonfibrotic HP from IPF, BAL fluid
lymphocyte thresholds of 20%, 30%, and 40% yielded sensitivities of 95%, 88%, and 67%,
respectively, and specificities of 61%, 80%, and 93% respectively, with an area under the curve
of 0.75 (95% CI 0.71-0.78) (Table 3).
To distinguish fibrotic HP from sarcoidosis, BAL fluid lymphocyte thresholds of 20%,
30%, and 40% yielded sensitivities of 69%, 55%, and 41%, respectively, and specificities of 26%,
43%, and 61% respectively, with an area under the curve of 0.44 (95% CI 0.41-0.47).To
distinguish nonfibrotic HP from sarcoidosis, BAL fluid lymphocyte thresholds of 20%, 30%, and
40% yielded sensitivities of 95%, 88%, and 76%, respectively, and specificities of 26%, 43%, and
61% respectively, with an area under the curve of 0.71 (95% CI 0.67-0.74) (Table 3).
The low AUC for fibrotic HP versus IPF and fibrotic HP versus sarcoidosis were a
consequence of the high standard deviations in many studies. As result, the populations of
fibrotic HP patients, IPF patients, and sarcoidosis patients also had a high standard deviation,
meaning that their distributions were wide and overlapping. A sensitivity analysis was
performed to assess potential inclusion bias (overestimation of sensitivity and specificity due to
the inclusion of studies that used BAL fluid lymphocytosis as a diagnostic criterion for HP); the
results remained the same, therefore the studies were kept in the final analysis.

Discussion

This is the only systematic review to date that has evaluated the performance of BAL fluid
lymphocyte cellular analysis in patients with newly detected ILD and then used the findings to
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inform multi-society clinical practice guideline recommendations. Notably, no relevant
randomized trials or controlled observational studies were identified; therefore, case series
that reported the percentage of BAL fluid lymphocytes in patients with HP and other ILDs
informed the guideline committee.
The systematic review demonstrated that the mean percentage of lymphocytes in the
BAL fluid of patients with HP was significantly higher than in patients with IPF; these differences
were greater among patients with nonfibrotic HP than fibrotic HP. Similarly, the mean
percentage of lymphocytes in the BAL fluid of patients with HP was significantly higher than in
patients with sarcoidosis; again, the difference was greater among patients with nonfibrotic HP
than fibrotic HP.
These findings are consistent with a study by Drent et al. [99], where sarcoidosis, HP,
and IPF could be discriminated from one another using various components of BAL fluid.
However, in contrast to our systematic review, Drent used the BAL fluid total cell count and
percentages of alveolar macrophages, lymphocytes, polymorphonuclear neutrophils,
eosinophils, and plasma cells in a discriminant analysis rather than the percentages of BAL fluid
lymphocytes alone. Welker et al. [100] also found that the BAL fluid cell differential can provide
substantial diagnostic information for conditions like sarcoidosis and those associated with
usual interstitial pneumonia (UIP), but found that it was less helpful for less frequent conditions
like HP.
The systematic review also demonstrated that a diagnostic cut-off of 20% BAL fluid
lymphocytes distinguishes nonfibrotic HP from both IPF and sarcoidosis with high sensitivity
(few false negative results), but the specificity was poor (many false positive results). This
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suggests that a 20% diagnostic threshold may be helpful at excluding nonfibrotic HP, but it
cannot be relied upon to confirm nonfibrotic HP. In contrast, the 20% diagnostic cut-off has
poor sensitivity and poor specificity for distinguishing fibrotic HP from either IPF or sarcoidosis.
Increasing to a 40% diagnostic threshold increases specificity and decreases sensitivity, but the
combination remains suboptimal for distinguishing either nonfibrotic or fibrotic HP from IPF
and sarcoidosis. Thus, our findings do not contradict or alter prior guidance, which advocated a
threshold of 20% BAL fluid lymphocytes to exclude non-fibrotic HP [101].
These findings are consistent with other studies. Adams et al. [102] and Morell et al.
[103] both reported that diagnostic cut-offs ranging from 20 to 40% had suboptimal sensitivity;
neither reported the specificity. Remy-Jardin et al. [104] reported that using 18% percent
lymphocytes in the BAL fluid as a diagnostic threshold had sensitivities of 100% and 91% for
nonfibrotic and fibrotic HP, respectively; specificity was not reported. The only study that
reported both sensitivity and specificity was Espoladore et al. [105], which found poor
sensitivity and specificity using 25% percent lymphocytes in the BAL fluid as a diagnostic
threshold. More recently, Adderley et al [106] reported that a 20% BAL fluid lymphocyte
threshold distinguished chronic HP from other ILDs with a sensitivity and specificity of 68.1%
and 64.8%, respectively. Our systematic review similarly found that a 20% BAL fluid lymphocyte
threshold distinguished fibrotic HP from IPF with a sensitivity and specificity of 69% and 61%,
respectively.
The main strength of this systematic review is that it was done as a part of guideline
development. Thus, in addition to all of the usual steps of a systematic review, the
methodology team interacted with international experts in the field and patient
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representatives to ensure that the question was clinically relevant, the outcomes were clinically
important, and no studies were missed whether published or part of the grey literature.
The systematic review has several important limitations. First, there were no
randomized trials or observational studies comparing BAL fluid lymphocyte cellular analysis to
no BAL fluid lymphocyte cellular analysis; thus, all data and conclusions were from case series
with non-consecutive enrolled patients that measured the percentage of lymphocytes in BAL
fluid and compared those values among patients with various ILDs. As a result, there is a serious
risk of selection bias. Second, many studies included exposure as a diagnostic criterion. Patients
with HP and an unidentified culprit exposure would have been unrepresented in such studies,
another potential cause of selection bias. Third, studies categorized patients as having acute,
subacute, or chronic HP, whereas the guideline committee categorized patients as having
nonfibrotic or fibrotic HP. This was managed by using acute and subacute HP as surrogates for
nonfibrotic HP and chronic HP as a surrogate for fibrotic HP, but this approach is inexact.
Fourth, studies that did indicate whether a patient had nonfibrotic or fibrotic disease usually
made the determination based upon chest radiographs, pulmonary function testing, and
duration of symptoms, which is likely insensitive compared to the method most often used
today, a CT scan of the chest. Fifth, several studies used BAL fluid lymphocytosis as a criterion
for the diagnosis of HP, potentially introducing inclusion bias. This was addressed by removing
the studies from the meta-analyses as a part of a sensitivity analysis, which did not reveal
definite inclusion bias. Nevertheless, it is possible that inclusion bias existed if the BAL fluid
lymphocyte percentage influenced the final diagnosis of HP in studies, even if it was not
described. Sixth, most studies did not report details about the site of BAL, the BAL technique, or
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whether patients were taking steroids or other immunosuppressants, all of which can affect the
BAL fluid lymphocyte percentage and could have been a source of heterogeneity. Seventh,
most studies did not report on complications associated with the BAL procedure, so the
committee was unable to systematically balance the potential benefits of BAL against the
potential harms of the procedure. Finally, the analysis to evaluate various thresholds of percent
BAL fluid lymphocytes for distinguishing HP (particularly fibrotic HP) from IPF and sarcoidosis
was hampered by the high standard deviations of the individual studies, leading to overlapping
populations and an inability to identify an optimal threshold.
The limitations of the systematic review highlight the need for better evidence.
Randomized trials or controlled observational studies should be conducted that directly
compare BAL fluid lymphocyte cellular analysis to no BAL fluid lymphocyte cellular analysis in
patient with ILD.
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Table 1. Evidence Profile for Hypersensitivity Pneumonitis versus Idiopathic Pulmonary Fibrosis
Quality assessment
No of
Design
studies

Risk of
bias

Summary of Findings

Inconsistency Indirectness Imprecision

Other

HP
(No.)

IPF
(No.)

Mean difference
(95% CI)

Quality

Importance

All - HP vs. IPF (% lymphocytes)
36 1

NRS

serious2

serious3

none

none

762

881

30.38
(26.78-33.99)


VERY
LOW

CRITICAL

none

none

none

258

290

20.81
(14.45-27.17)


VERY
LOW

CRITICAL

none

none

none

139

171

34.21
(28.66-39.76)


VERY
LOW

CRITICAL

none

none

none

365

420

35.77
(26.78-33.99)


VERY
LOW

CRITICAL

none

Fibrotic/chronic HP vs. IPF (% lymphocytes)
12 4

NRS

serious2

serious3

Non-fibrotic/acute/subacute HP vs. IPF (% lymphocytes)
95

NRS

serious2

serious3

Non-specified HP vs. IPF (% lymphocytes)
156

NRS

serious2

serious3

Abbreviations: HP- hypersensitivity pneumonitis, IPF- idiopathic pulmonary fibrosis, CI- confidence interval, AUC- area under curve, and NRS- non-randomized
study
Explanations:
1 Studies included, references 15-26, 30-38, and 45-59.
2 Multiple studies had a serious risk of bias due to lack of enrollment of consecutive patients, as shown in the selected studies table.
3 Even after the removal of outliers, the I2 statistic was >50%.
4 Studies included, references 15-26.
5 Studies included, references 30-38.
6 Studies included, references 45-59.
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Table 2. Evidence Profile for Hypersensitivity Pneumonitis versus Sarcoidosis
Quality assessment
No of
Design
studies

Risk of
bias

Summary of Findings
Quality

Importance

19.32
(17.28-21.36)


VERY
LOW

CRITICAL

15.68
(11.25-20.1)


VERY
LOW

CRITICAL

326

643

24.58
(22.07-27.1)


VERY
LOW

CRITICAL

215

1249

17.68
(17.28-21.36)


VERY
LOW

CRITICAL

524

Other

HP
(No.)

Sarcoid
(No.)

Mean difference
(95% CI)

none

none

904

2208

none

none

165

none

none

none

none

Inconsistency Indirectness Imprecision

HP vs. Sarcoidosis (% lymphocytes)
531

NRS

serious2

serious3

none

Fibrotic/chronic HP vs. Sarcoidosis (% lymphocytes)
164

NRS

serious2

serious3

none

Non-fibrotic/acute/subacute HP vs. Sarcoidosis (% lymphocytes)
175

NRS

serious2

serious3

none

Non-specified HP vs. Sarcoidosis (% lymphocytes)
216

NRS

serious2

serious3

none

Abbreviations: HP- hypersensitivity pneumonitis, CI- confidence interval, AUC- area under curve, and NRS- non-randomized study
Explanations:
1 Studies included, references 15,18-19,22-23,29-32,36-37,39,44-50,52-54,57-60,64,66-70,73-84,86-87,89-90,92-93,95-96,98.
2 Multiple studies had a serious risk of bias due to lack of enrollment of consecutive patients, as shown in the selected studies table.
3 Even after the removal of outliers, the I2 statistic was >50%.
4 Studies included, references 15,18-19,22-23,29,75,78-84,96,98.
5 Studies included, references 30-32,36-37,44,64,66-70,73-77.
6 Studies included, references 39,45-50,52-54,57-60,86-87,89-90,92-93,95.
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Table 3. Assessment of Various Diagnostic Thresholds of Percentage of BAL Fluid Lymphocytes
Fibrotic HP vs. IPF
20%
lymphocytes
30%
lymphocytes
40%
lymphocytes

Non-fibrotic HP vs. IPF

Fibrotic HP vs.
sarcoidosis
Sensitivity
Specificity

Non-fibrotic HP vs.
sarcoidosis
Sensitivity
Specificity

Sensitivity

Specificity

Sensitivity

Specificity

69%

61%

95%

61%

69%

26%

95%

26%

55%

80%

88%

80%

55%

43%

88%

43%

41%

93%

76%

93%

41%

61%

76%

61%

AUC 0.54
(95% CI 0.51-0.58)
N = 1238

AUC 0.75
(95% CI 0.71-0.78)
N = 1202

AUC 0.44
(95% CI 0.41-0.47)
N = 2565

Abbreviations: AUC= Area Under the Curve, CI= Confidence Intervals, N= Number of Subjects
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Figure 1. Flow of Information Diagram
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Figure 2. Mean BAL lymphocyte % in patients with HP, compared to patients with Idiopathic Pulmonary Fibrosis
A) Before outliers removed

B) After outliers removed
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Figure 3. Mean BAL lymphocyte % in patients with HP, compared to patients with Sarcoidosis
A) Before outliers removed

B) After outliers removed
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7Division of Respiratory Medicine, University of Nottingham, Nottingham, UK
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Table E1. Literature search strategy
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to April 01, 2019>

#

Searches

Results

1

alveolitis, extrinsic allergic/ or bird fancier's lung/ or farmer's lung/ or silo filler's disease/ or trichosporonosis/ [Medline]

4137

2

allergic pneumonitis/ or bird breeder lung/ or farmer lung/ or loeffler pneumonia/ or pigeon breeder lung/ [Embase]

1516

3

5224

5

((hypersensitiv$ or allerg$ or lymphocyt$ or granulomat$) adj2 (pneumoni$ or alveolit$)).mp.
((chemical or coffee or detergent or laboratory or malt or metal or mushroom or peat moss or poultry or sauna or tobacco) adj (worker$ or handler$)
adj3 (pneumoni$ or lung$ or respirat$ or pulmon$)).mp.
((bird breeder$ or pigeon breeder$ or bird fancier$ or brass player$ or cheese washer$ or compost or farmer$ or hot tub or humidifier or Japanese
summer$ or metalwork$ or miller or millers or mollusk shell$ or potato peeler$ or saxophone$ or snuff taker$ or tap water or trombone$ or well
emptier$ or wine grower$ or woodworker$) adj3 (pneumoni$ or lung$ or respirat$ or pulmon$)).mp.

6

(lycoperdonosis or sequoiosis or suberosis or trichosporonos$ or silo filler$ or Streptomyces or ((maple bark or thatched roof) adj disease$)).mp.

27356

7

3 or 4 or 5 or 6 [HP textwords]

33750

8

1 or 7 [all HP Medline]

33750

9

2 or 7 [all HP Embase]

33750

10

bronchoalveolar lavage/ or bronchoalveolar lavage fluid/

26853

11

((lavage$ or wash$) adj2 (lung$ or bronch$ or pulmonary)).mp.

42950

12

10 or 11 [lavage]

42950

13

8 and 12 [HP and lavage]

4

98

2015

1342
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Table E2: Steps for Study selection
Steps for study
selection
First

Study Type

Study Objective

Studies Identified

Literature search with predefined literature
1500
strategy
Second
Systematic Reviews Aggregate randomized controlled trials that
None
compared BAL fluid lymphocyte cellular analysis
to no BAL fluid lymphocyte cellular analysis in
patients with newly detected ILD
Third
Randomized
Compare BAL fluid lymphocyte cellular analysis None
Controlled Trials
to no BAL fluid lymphocyte cellular analysis in
patients with newly detected ILD
Fourth
Observational
Compare BAL fluid lymphocyte cellular analysis None
Studies*
to no BAL fluid lymphocyte cellular analysis in
patients with newly detected ILD
Fifth
Case Series**
Enroll >20 patients with known ILDs and report
340
BAL lymphocyte counts
Sixth
Case series (340
Additional restrictions added:
84
selected in the prior  English Language
step)
 Studies reporting lymphocyte count of
patients with HP as well as either IPF or
Sarcoidosis or both.
 Lymphocyte count reported as a percentage of
the total white cell count
*Observational studies require a control group; generally speaking, this category includes prospective cohort studies, retrospective
cohort studies, case-control studies, and before-and-after studies.
**Case series do not include a control group.
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Table E3. Selected studies

Author

Type of
study

Number of
subjects

Location

Interve
ntion

Definition of HP

Etiology of HP

Outcomes

(a) a history of exposure to HP antigens; (b) clinical features,
including fever, headache, malaise, "tightness" of the chest,
and breathlessness on effort 4 to 8 hours after exposure;(c)
abnormalities in the chest film and/or cases,
Thermoactinomyces vulgaris in one case, and pigeon proteins
in one case
1) exposure to HP Ag; 2) symptomatic acute episode with
chills, fever, cough and breathlessness 4 to 8 hours after
exposure; 3) radiologic features (mainly diffuse reticular
pattern) and/o functional pattern of ILD; 4) and evidence of
antibodies against micropolyspora faeni in all cases. BAL done
at least one month after acute episode
History of antigen exposure, typical clinical features (dyspnea,
cough, fever, chills), and the presence of allergen-binding IgG.

6 farmer's lung,
one mushroom
worker's lung,
and one pigeon
breeder's
disease.
Famer's lung
disease.

BAL

Not specified.

BAL

cell count
and
differential

Famer's lung
disease with
recent
exposure to
antigen.
8 Farmer's lung
disease and 3
mushroom
farm workers.

BAL

cell count
and
differential

BAL

Cell count
and
differential

20 bird fanciers
and 4 had
farmer's lung.

BAL

Risk of bias
0 = no risk of bias
1 = serious risk of
bias
2 = very serious risk
of bias

Acute/subacute/non-fibrotic HP (n=28)
Agostini
1987

NRS

Italy

Agostini
1996

NRS

Baumer
1998

NRS

Germany

HP=12,
sarcoidosis=41,
TB=20, control=26

Bertorell
i 1988

NRS

Italy

sarcoidosis=19,
HP=11, IPF=8

History of exposure to antigens, clinical and radiological
features of ILD and antibodies against micropolyspora faeni
were always observed. In all patients, biopsy material was in
agreement with HP.

Cantin
1984

NRS

Canada

HP=11,
sarcoidosis=23,
control=32

Typical acute illness after exposure to the antigen, compatible
CXR, transbronchial lung biopsy, and the presence of positive
precipitin to Mycroployspora faeni or Thermoactinomyces.ACE
was normal in all patients in this group. All the patients in this
group had persistent respiratory and systemic symptoms at
the time of evaluation. Evaluation occurred within 2 months of
onset of acute illness, in all cases with cessation of exposure to
the antigen.
History, clinical and radiological features and functional
pattern of ILD. All had precipitins against the relevant antigen.

Costabel
, U.,
1992

NRS

Italy

HP=8,
sarcoidosis=21,
normal=5

Germany

HP=8,
sarcoidosis=10,
HIV=9, Control=7

HP=24, IPF=22,
COP=10, chronic
eosinophilic
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BAL

cell count
and
differential

cell count
and
differential

Lymphocyt
e count
and
proportion

No risk of bias

Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
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Couto et
al . 2015

NRS

Drent
1996

NRS

Fujishim
a 2004

NRS

Japan

Hamaga
mi 1992

NRS

Japan

Haslam
1990

NRS

England

Heron
2009

NRS

Netherlan
ds

Hoogste
den
1993

NRS

Kombac
h 1996

NRS

Germany

Kucejko
2009

NRS

Poland

Magdale
na 2003

NRS

Portugal

Netherlan
ds

Netherlan
ds

Poland

pneumonia=9,
control=10
Suspected ILD
patient with BAL
as initial work up.
HP=20,
Sarcoidosis = 41,
Interstitial
pneumonitis=16.
Learning set
sarcoidosis= 190,
HP=38, IPF=44;
Test set
sarcoidosis=91,
HP=5, IPF=32
HP=7,
sarcoidosis=24,
control=15
HP=12,
sarcoidosis=11,
IPF=10, CTDILD=4, COP=2
HP=13,
sarcoidosis=23,
fibrosing
alveolitis=12,
control=7
HP=7,
sarcoidosis=23,
control=24
HP=9,
sarcoidosis=10,
IPF=8, control=10
Sarcoidosis=19,
HP=10, IPF=29,
CTD-ILD=19,
control=10
HP=9,
sarcoidosis=27,
IPF=7

HP=9,
sarcoidosis=18,
IPF=10

Diagnosis of HP based on Schuyler and Cormier criteria. HRCT
was classified as presenting GGO, mosaic pattern and fibrosis
(Selman PATS 2010)

Bird
fanciers=14,
suberosis/other
work-related
antigens=5.

BAL

Clinical information, CXR, PFT, precipitins in peripheral blood,
disappearance of symptoms after avoidance of the causative
antigen. Recent contact but not within 48 h before BAL

Not specified.

BAL

recurrent acute exacerbation of clinical symptoms following
exposure to antigens, a ground-glass shadow on chest X-ray
and thoracic computed tomography, BALF cell lymphocytosis,
and histological evidence of granuloma formation
Appearance of symptoms in Summer, cough, remittent fever
and dyspnea following exposure to the causative allergens,
diffuse nodular shadows on CXR, detection of anti- C
neformans/anti T cutaneum antibody activity in the serum
Lung biopsy (2 open lung biopsy)

Not specified.

BAL

cell count
and
differential

Not specified.

BAL

cell count
and
differential

8 related to
exposure to
bird, 3 related
to mold

BAL

cell count
and
differential

All respiratory symptoms including dyspnea or cough, +/- fever
and arthralgia after exposure to birds; precipitating Ab to birds
and lymphocytic alveolitis (>15% lymphocytes in BAL)
History of exposure to organic dust followed by exposurerelated respiratory symptoms, specific precipitating antibodies
to antigen of the particular dust. Antigen exposure 4 days or
less prior to the lavage.
Clinical and radiological findings, PFT and transbronchial
biopsies

Bird Fancier’s
Lung

BAL

Not specified.

BAL

cell count
and
differential
cell count
and
differential

Not specified.

BAL

cell count
and
differential

In 6 cases transbronchial lung biopsy was performed to collect
histological samples. Histological examinations revealed
inflammatory cells infiltrations, and in one case, interalveolar
septa fibrosis. In every case serological tests were performed
to assess the presence of specific precipitins in serum.
History of antigen exposure, presence of serum IgG to these
antigens, physical exam, CXR and HRCT. 3 had lung open
biopsy. 1 received steroids at the time of BAL

Not specified.

BAL

cell count
and
differential

Not specified.
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BAL

Lymphocyt
e count
and
proportion

cell count
and
differential

cell count
and
differential

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
No risk of bias

No risk of bias
Serious risk of bias
due to nonconsecutive
enrollment

No risk of bias

Serious risk of bias
due to non-
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Ohtsuka
1994

NRS

Japan

Sarcoidosis=12,
HP=12, control=13

Japanese summer-type HP in acute stage and diffuse nodular
infiltrates on chest films, CRP and subjective symptoms

Not specified.

BAL

cell count
and
differential

Okamot
o 2015

NRS

Japan

Acute HP=35,
IPF=54, CTDILD=67,
sarcoidosis=47

Reproduction of symptoms by an environmental provocation
or laboratory-controlled inhalation of a causative antigen
and/or antibodies or lymphocyte proliferation to the
presumptive antigens, evidence of pulmonary fibrosis on a
pathological examination, and respiratory symptoms related
to HP for 6 months or longer. Patients with the recurrent type
experience repeated acute episodes accompanied by fever.
The insidious type has a slowly progressive course without
acute episodes.
HP was diagnosed in patients who presented specific serum
IgG antibodies to Pigeon serum (11 patients), Aspergillus
fumigatus (5 patients) or Saccharopolyspora rectivirgula (3
patients) and compatible BALF and HRCT findings, based on
the criteria by Lacasse et al.17 Twelve patients suffered from
acute and seven from subacute HP.
criteria of Salvaggio and Karr for this syndrome

Not specified.

BAL

cell count
and
differential

Papakos
ta 2014

NRS

Greece

PerezArellano
1993

NRS

Pforte
1993

NRS

Germany

Shinohar
a 2018

NRS

Japan

Spain

HP=19, IPF=38,
COP=26

HP=5,
sarcoidosis=10,
IPF=5, diffuse
neoplastic
infiltration of the
lung=8, Control=8
HP=20,
sarcoidosis=20,
IPF=14, CTDILD=5, control=6
HP=4,
sarcoidosis=11,
=chronic
eosinophilic
pneumonia=8,
drug-induced
eosinophilic
pneumonia=3,
COP=9, idiopathic
fibrosing
interstitial
pneumonia (NSIP
and UIP=5

The diagnosis was based on a history of antigen exposure,
typical clinical features of acute disease precipitating
antibodies against the relevant allergens, and histological
examination of lung biopsies. T
clear evidence of exposure, clinical beahviro consistent with
HP, BAL lymphocytosis, poorly defined round centrilobular
nodules, GGO on HRCT, improvement after refuge from
suspected environment, and histological findings consisten
with HP such as noncaseating granulomas with nucleated giant
cells and the infiltration of lymophcytes

Not specified.

BAL

2 patients with
bird fancier's
lung, 1 case of
farmer's lung,
and 2 cases of
plasterer's lung.
Not specified.

BAL

1 mushroom
worker, 1
greenhouse
worker, 1
patient who
was serum
positive
for antiTrichosporon
cutaneum
antibodies, and
1 patient with
unknown
particle
exposure.

BAL
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BAL

cell count
and
differential

cell count
and
differential

Lymphocyt
e count
and
proportion
cell count
and
differential

consecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
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Japanes
e

NRS

Taniuchi
2009

NRS

Japan

Japan

Unoura
2011

NRS

Japan

Uzaslan
2003

NRS

Germany

Valenti
1982

Yamashi
ta 2015

NRS

NRS

Italy

Japan

HP=5, sarcoidosis16, COP=7,
chronic interstitial
pneumonitis=13,
CTD-ILD=19,
AIP=5, IPF=21,
control=10
HP=14,
sarcoidosis=76

Criteria by Ando Am Rev Respir Dis 1991; 144: 765±769

Lung biopsy

Acute HP=10,
sarcoidosis=10,
CTD-ILD=17, other
lung disease=8,
control=8
HP=14,
sarcoidosis=11,
IPF=10, control=7

Ando 1991, Yoshizawa 1999 guidelines.

HP=9, active
sarcoidosis=20,
inactive
sarcoidosis=15,
control
smokers=6,
control nonsmokers=6
HP=26, IPF=4,
Control=29

Not specified, but included specific precipitins, restrictive
ventilatory defect, BAL and transbronchial biopsies.

History of exposure to organic dust, exposure-related
symptoms, radiologic features and the functional
characteristics of ILD, and evidence of precipitating serum
antibodies against the suspected antigen.

Used criteria proposed by Richerson. The history and physical
findings and pulmonary function tests indicate an interstitial
lung disease, (2) the x-ray film is consistent, (3) there is
exposure to a recognized cause, and (4) there is antibody to
that antigen.

Japanese
Summer-type
HP.

BAL

4 Summer type
HP, 4
hypersensitivity
to chemical
material, 1 to
feather of
bedding, 5
unknown but
symptoms
provoked when
exposed at
home or work
Not specified.

BAL

BAL

Lymphocyt
e count
and
proportion

11 suffered
from
budgerigar
fancier's lung, 2
from pigeon
breeder's lung,
and 3 patients
had farmer's
lung.
Not specified.

BAL

Lymphocyt
e count
and
proportion

Not specified.
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cell count
and
differential

Serious risk of bias
due to nonconsecutive
enrollment

cell count
and
differential
Serious risk of bias
due to nonconsecutive
enrollment

BAL

BAL

Lymphocyt
e count
and
proportion

Lymphocyt
e count
and
proportion

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
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Chronic/fibrotic HP (n=24)
Bellange
r 2016

NRS

Dai 2005

NRS

France

Germany

HP=16, IPF=11,
Sarcoid=12

HP=12,
sarcoidosis=10,
control=9

Delacroi
x 1985

NRS

Belgium

Furasaw
a 2017

NRS

Japan

HP=4, inactive
sarcoidosis=4,
active
sarcoidosis=13
HP= 5, IPF=101

Groot
Kormeli
nk 2011

NRS

Mexico

HP=22, IPF=21

Hamm
1994

NRS

Germany

HP=10,
sarcoidosis=35,co
ntrol=10

Korosec
2007

NRS

Slovenia

HP=17,
sarcoidosis=57

Leather
man
1984

NRS

USA

Lehtone
n 2014

nrs

Finland

HP=6,
Assymptomatic
breeders=5,
Sarcoidosis=6,
control=8
HP=3,
sarcoidosis=17,
IPF=14, NSIP=10,
CTD-ILD=9,
control=12

All HP were chronic forms and diagnosis was based on clinical
course, insidious onset over months, history of antigen
exposure, and radiological data following international
guideline
Diagnostic criteria for EAA were as follows: (1) a history of
exposure to organic antigens, (2) clinical signs and symptoms
consistent with EAA, (3) radiologic features and/or functional
abnormalities characteristic of interstitial lung disease, (4)
evidence of serum precipitins against one or more organic
antigens, and (5) BAL with increased lymphocytes (� 40%).
Not specified

Not specified.

Not specified.

BAL

cell count
and
differential

Not specified

Not specified.

BAL

cell count
and
differential

history of pigeon exposure and positive serum antibodies
against avian antigens; clinical, radiological, and functional
features of an ILD with >6 months of symptoms; 30%
lymphocytes in BAL fluid; and d) lung histology compatible
with HP.
individual patient's history with adequate exposure to
compatible antigens and exposure -related symptoms,
serologic evidence of precipitating antibodies against the
offending materials, abnormal chest x-ray films with signs of
interstitial lung disease, restrictive patterns in lung function
tests, and atypical lymphocytic alveolitis with low or normal
CD4:CD8 ratios in BAL fluids.
Refer to Lacasse. Am J Respir Crit Care Med 2003; 168:952–
958

Not specified.

BAL

cell count
and
differential

Not specified.

BAL

cell count
and
differential

Not specified.

BAL

cell count
and
differential

Not specified

Not specified.

BAL

cell count
and
differential

Not specified

Not specified.

BAL

cell count
and
differential

Not specified.
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BAL

BAL

cell count
and
differential
cell count
and
differential

No risk of bias

No risk of bias

Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
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Markart
2009

nrs

germany

HP=7, IPF=16,
Sarcoidosis=12,
Control=20

Morell
2013

NRS

Spain

HP=20, IPF=26

Nukui
2019

NRS

Japan

HP=32, IPF=8

Ohshim
oto 2009

NRS

Germany

HP=3, IPF=68

Okamot
o 2015

NRS

japan

Chronic HP=57,
IPF=54, CTDILD=67,
sarcoidosis=47

Pesci
1993

NRS

Italy

HP=15, COP=6,
Sarcoidosis=16,
Control=7

Przbylski
2015

NRS

Germany

HP=6, IPF Non
smoker=10, IPF
smoker=8, IPF
treated=5, NSIP
non smoker=9,
NSIP treated=9,
COP=8,
Sarcoidosis non
smoker=24,
Sarcoidosis
smoker=21,

evidence of exposure to appropriate antigen by history,
investigation of the environment, serum precipitin test, and/or
BAL fluid antibody; BAL fluid lymphocytosis; and positive
"natural challenge", or by controlled inhalational challenge
Clinical + radiological criteria: 1) positive bronchial challenge
test, or 2) IgG positivity, >20% BAL lymphocytes, or 3)
histopathology of HP
Does not mention- but cites other article. The current
diagnostic criteria for chronic HP was 3 or more of the
following (including 5, either 2 or 3, and either 1 or 6): (1)
reproduction of symptoms of HP by an environmental
provocation or laboratory-controlled inhalation of the
causative antigen; (2) evidence of pulmonary fibrosis with or
without granulomas; (3) honeycombing on computed
tomography scans; (4) progressive deterioration of a restrictive
impairment on pulmonary function over 1 year; (5) over 6
months duration of respiratory symptoms related to HP; or (6)
antibodies and/or lymphocyte proliferation to the presumptive
antigen. T
Not specified

Not specified.

BAL

cell count
and
differential

Not specified.

BAL

cell count
and
differential
cell count
and
differential

Not specified.

BAL

cell count
and
differential

The diagnostic criteria for chronic HP included clinical
improvement after withdrawal from the suspected
environment and/or reproduction of symptoms by an
environmental provocation or laboratory-controlled inhalation
of a causative antigen and/or antibodies or lymphocyte
proliferation to the presumptive antigen, evidence of
pulmonary fibrosis on a pathological examination or on
computed tomography (CT) scans, and respiratory symptoms
related to HP for 6 months or longer
history of exposure to moldy hay; (2) clinical and radiologic
features and/or functional pattern of interstitial lung disease;
and (3) evidence of antibodies against Micropolyapora faeni.

Not specified.

BAL

cell count
and
differential

Farmer's lung
disease.

BAL

cell count
and
differential

EAA was diagnosed on the basis of clinical data, including
typical symptomatology following allergen exposure, the
presence of specific antibodies in serum, typical HRCT findings,
and lung function test results. In 5 patients (71%), the
diagnosis was confirmed by lung biopsy.

Not specified.

BAL

cell count
and
differential

Not specified.

BAL

Serious risk of bias
due to nonconsecutive
enrollment
No risk of bias

Serious risk of bias
due to nonconsecutive
enrollment
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Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
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Schmidt
2002

NRS

Germany

Sharma
1989

Sterclov
a 2009

NRS
NRS

India
Czech
Republic

sarcoidosis
treated=7, Control
non smoker=7,
control smoker=6
HP=5,
sarcoidosis=12,
IPF=12, Control=8
Chronic HP=3,
sarcoidosis=36,
cryptogenic
fibrosing
alveolitis=15,
silicosis=6,
carcinomatosis=10
, TB=7, tropical
pulmonary
eosinophilia=6,
fibrosing alveolitis
due to collagen
vascular
disease=5,
alveolar
microlithiasis=1
HP=16, IPF=7

Sterclov
a
2009_1

NRS

Czech
Republic

HP=6,
Sarcoidosis=13,
control=15

Sterclov
a 2013

NRS

Czech
Republic

HP=14,
Sarcoidosis=6

Unoura
2011

NRS

Vasakov
a 2008

NRS

Japan
Czech
Republic

Chronic HP=19,
sarcoidosis=10,
CTD-ILD=17,
control=8
HP=11,
sarcoidosis=22,
IPF=6

proof of a hypersensitivity response to an inhalative antigen
(history of periodically recurring or permanent complaints on
exposure, in combination with the detection of precipitating
antibodies)
Clinical history, physical and radiological examination.
Exposure to pigeons, serum precipitins were positive, and
there was upper lobe involvement in CXR.

4 patients with
avia-induced
HP and 1 with
farmer's lung.
Not specified.

BAL

cell count
and
differential

BAL

cell count
and
differential

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

exposition to suspect antigen, symptoms, physical findings,
radiographic abnormalities, pulmonary function, immunologic
tests and BAL. Lung biopsy was performed when diagnosis was
not definite (2 EAA patients)
History of exposition to antigen, symptoms, physical findings,
HRCT, Immunologic tests (specific IgG), BAL, lung biopsy
Possible chronic EAA: negative history of exposure to
inhalation antigen+ BALF lymphocytosis+typical HRCT
pattern/histology pattern ::::::Probable chronic EAA: positive
history of exposure to inhalation antigen+typical
HRCT/histology pattern::::::::::Definite chronic EAA: positive
history of exposure to inhalation antigen+BALF
lymhocytosis+typical HRCT/ histology pattern
Ando 1991, Yoshizawa 1999 guidelines.

Not specified.

BAL

Not specified.

BAL

cell count
and
differential

Not specified.

BAL

cell count
and
differential

Not specified.
BAL

History of exposition to antigen, typical clinical course, HRCT,
specific IgG, BAL cell count. Videothoracoscopic lung biopsy in
3 patients

cell count
and
differential

Not specified.
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BAL

cell count
and
differential
cell count
and
differential

No risk of bias
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
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Willems
2013

NRS

Belgium

HP=11, IPF=11,
Control=10

Patients were diagnosed with chronic HP based on their
clinical course and insidious onset over a period of months,
history of antigen exposure, radiological, and/or
histopathological data.

Not specified.

BAL

cell count
and
differential

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Non-specified or mixed acute/subacute/non-fibrotic + chronic/fibrotic HP (n=31)
Bargagli
2007

NRS

Italy

Cai 2013

NRS

China/Ger
many/Spa
in

Costabel
1985

NRS

Drent
1997

NRS

Germany

Netherlan
ds

Espolad
ore 2014

NRS

Brazil

Fireman
1994

NRS

Israel

Fujimori
2003

NRS

Japan

HP=7,
sarcoidosis=22,
IPF=15,
scleroderma=13
Acute HP=12,
Chronic HP=22,
IPF=54, iNSIP=30,
RB-ILD=11,
Sarcoidosis=26,
control=44
HP=9, active
sarcoidosis=17,
inactive
sarcoidosis=12,
control=9

Refer to Richerson. J Allergy Clin Immunol 1989; 84:839–844

Not specified.

BAL

cell count
and
differential

History of exposure, clinical signs, radiological features of ILD,
serum precipitin, BAL lymphocytosis- (12 acute and 22 chronic.
However, BAL results are not specified by subgroup)

Mixed.

BAL

cell count
and
differential

History, clinical, radiologic and functional patter of ILD, all had
precipitins against the relevant antigen

HP=54 (<24h=14,
2-7 d=23, 8-30
d=11, 1-12
months=6),
sarcoidosis=77,
control=11

Clinical information, CXR, precipitating serum antibodies
against suspected antigens, PFT, and disappearance of
symptoms after avoidance of antigen exposure. Open lung
biopsy was performed in 6 patients without sufficient clinical
criteria to make a definitive diagnosis. Antigen provocation
was achieved by bringing the patient into contact with the
birds, followed by BAL within 24h.Study criteria were BAL of
sarcoid and EAA showing Lymph count > 15% were included in
the study.
Clinical diagnoses were executed according to the criteria
suggested by the Brazilian Thoracic Society and in several
cases by multidisciplinary discussion.

Mixed. 6
parakeet
fanciers, 2
pigeon
breeders, 1
humidifier lung.
Not specified.

HP=15,
sarcoidosis=12,
IPF=14, CTDILD=24, SR=ILD=8,
aspiration=8,
other=10
HP=3, untreated
sarcoidosis=6,
diffuse interstitial
fibrosis=3,
control=6
HP=9,
sarcoidosis=25,
idiopathic
interstitial

Mixed.

BAL

BAL

BAL

cell count
and
differential

cell count
and
differential

cell count
and
differential

CXR and CT scan showed reticular nodular patter with
predominant upper zone, BAL demonstrated lymphocytosis,
lung histology compatible with HP, no attempt to characterize
sensitizing antigen

Not specified.

BAL

cell count
and
differential

history, physical examination, CXR, CT, histology including
transbronchial biopsy

Not specified.

BAL

cell count
and
differential
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No risk of bias

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
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Godard
1981

NRS

France

Gunther
1999

NRS

Germany

Hill 2004

NRS

Mexico

pneumonia=18
(UIP=13, NSIP=5),
CTD-ILD=15,
control=12
HP=6,
sarcoidosis=16
patients with
untreated ILD at
the time of lavage.
HP=32, IPF=36,
sarcoidosis=44,
control=29
HP=115 (pigeon
breeders' disease),
IPF= 94,
control=323,
subjects with
avian exposure=90

Hoogste
den
1989

NRS

Netherlan
ds

HP=7,
sarcoidosis=20,
IPF=18, control=12

Kopinski
2011

NRS

Poland

MILMA
N 1995

NRS

Denmark

HP=12,
sarcoidosis=89,
IPF=23, NSIP=6,
silicosis=7,
asbestosis=8
HP=6,
Sarcoidosis=77,
cryptogenic
fibrosing
alveolitis=7,
secondary
fibrosing
alveolitis=7,
malignancy=7
HP=7,
sarcoidosis=17,
IPF=10, CTDILD=6, COP=3,

Nagata
1996

NRS

Japan

Clinical, radiologic, and immunologic evidence of disease. No
biopsy

Not specified.

BAL

cell count
and
differential

Major criteria: 1) history of periodically recurring or
permanent complaints upon exposure to an inhaled antigen;
2) detection of precipitating antibodies; 3) patchy interstitial
infiltrates in both lungs by chest radiography or CT/HRCT; and
4) elevated BAL lymphocyte counts with decreased CD4/ CD8
ratio.
Does not mention directly but cites other article- their criteria
were- Diagnosis of PBD was established according to the
following criteria : (1) exposure to pigeon preceding the
beginning of the disease, and positive serum antibodies to
avian antigens, as detected by ELISA (20); (2) progressive
dyspnea with partial improvement after avoidance of the avian
antigen exposure; (3) clinical, radiological, and functional
features of an interstitial lung disease; (4) more than 40% of
lymphocytes in the bronchoalveolar lavage; and (5) lung
histology compatible with HP. 72 HP patients had surgical lung
biopsy.
History of exposure to organic dusts followed by exposurerelated respiratory symptoms, precipitating antibodies to
antigens to the particular dust were present, exposure to dust
within 3 days of BAL.
Clinical data, symptoms after allergen exposure, detection of
specific antibodies in serum, typical presentation in HRCT, and
lung function test. In some cases HP was confirmed by lung
biopsy

Not specified.

BAL

cell count
and
differential

Clinical, paraclinical tests, transbronchial lung biopsies

Environmental and occupational history, clinical course, CXR
and CT findings, immunologic tests.

Not specified.
Pigeon
breeders'
disease.

BAL

Not specified.

BAL

cell count
and
differential

Not specified.

BAL

cell count
and
differential

Not specified.

BAL

cell count
and
differential

Not specified.
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BAL

cell count
and
differential

cell count
and
differential

Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment

Very serious risk of
bias due to nonconsecutive
enrollment and all
participants were
female

Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
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Oshima
1999

NRS

Japan

Pardo
2001

NRS

Mexico

Phelps
2004

NRS

Mexico

Raulf
1993

NRS

satake
1993

NRS

Germany

Japan

chronic
eosinophilic
pneumonia=1,
unclassified
diffuse pulmonary
fibrosis=2,
pneumoconiosis=9
. Patients with IPF,
CTD-ILD, COP, CEP
and unclassified
diffuse pulmonary
fibrosis were
analyzed together
as having
intersitial
pneumonitis/fibro
sis=22
HP=4,
sarcoidosis=17,
cryptogenic
fibrosing
alveolitis=10
Subacute and
chronic HP=10,
IPF=9
HP 22, IPF 26,
Control 9

HP=13,
sarcoidosis=31,
IPF=12, control=21

HP=12,
sarcoidosis=26,
COP=13,
control=40

Compatible history, physical examination, chest radiographic
findings, positive anti-Trichosporon antibody in serum

Did not specify.
Summer type
HP.

BAL

cell count
and
differential

Pardo. AJRCCM 2000; 161:1698-1704

Mixed.

BAL

cell count
and
differential

HP diagnostic criteria included BAL lymph count > 40%. Also
included biopsy consistent with HP (results sectin however
mentions- "In the HP group, differential cell counts in BAL
fluid were characterized by a marked lymphocytosis usually
40%, while in IPF most BAL inflammatory cells were
macrophages"
Diagnoses based on typical case histories, presence of antigenspecific antibodies, abnormal CXR, restrictive ventilation
pattern, and transbronchial biopsy.

Not specified.

BAL

cell count
and
differential

Clinical findings and transbronchial biopsies. All cases of
summer-type HP detected Trichosporon cutaneum in sera,
restrictive PFT pattern, and GGO in CXR

Mixed.
Farmers' lung
disease=6,
isocyanate
alveolitis=1,
and
bird/pigeon
fanciers'
lung=6.
Not specified. 9
patients with
summer-type
HP, 1 with bird
fanciers' HP, 2
with HP due to
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BAL

BAL

cell count
and
differential

cell count
and
differential

Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
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Schildge
, J., 2007

NRS

Semenz
ato 1985

NRS

Sherson
1992

NRS

Germany

Italy

Denmark

Shiota
1987

NRS

Japan

Sokhats
ka 2019

NRS

Portugal

HP=51,
sarcoidosis=236,
IPF=85, COP=83,
CTD-ILD=64, RBILD=54,
controls=45
HP=7,
sarcoidosis=26
(Based on T-cells
on BAL >28% and
Ga scan positive->
high intensity
alveolitis=13, low
intensity
alveolitis=13)

not specified

HP=7,
sarcoidosis=19,
IPF=15,
pneumoconiosis=6
, control=5

not specified

HP=9,
sarcoidosis=6,
asthma=24,
control=19
HP=53,
sarcoidosis=106,
IPF=8, CTDILD=25, COP=10

Clinical history, laboratory and histological examination.

History of exposure to HP antigens, clinical and radiologic
features with functional patter of ILD, and evidence of
antibodies against one or more relevant antigens.

HP clinical diagnosis based on Lacasse. All 202 patients had
lymphocytes >15% in BAL for diagnosis of alveolitis.

airconditioning.
Not specified.

BAL

cell count
and
differential

No specified. 6
patients had
farmer's lung
and 1 had
pigeon
breeder's
disease. All
were studied
more than 2
months after
the last
exposure to the
etiologic
antigens.
not specified. 2
patients had
nitrofuraoininduced
disease, 2 had
bird fancier’s
disease, 3 had
exposure to
Faeni
rectivigula
(Micropolyspor
a faeni).
Not specified.

BAL

BAL

cell count
and
differential

Not specified.

BAL

cell count
and
differential
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Serious risk of bias
due to nonconsecutive
enrollment

cell count
and
differential

Serious risk of bias
due to nonconsecutive
enrollment

BAL

cell count
and
differential
Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
Very serious risk of
bias due to nonconsecutive
enrollment and
exclusion of patients
with a BAL
lymphocyte count
<15%
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SOLER
1987

Sterclov
a 2015

Thomee
r 2004

Tondell
2015

NRS

NRS

NRS

NRS

France

Czech
Republic

Belgium

Norway

HP=20 ,
sarcoidosis=92,
histiocytosis X=12,
control=15

HP=121 (divided
by age- < 30 yo=8
(subacute HP=8
and chronic
HP=0), 30-60
yo=49 (subacute
HP=24 and chronic
HP=25), > 60
yo=64 (subacute
HP=17 and chronic
HP=47),
sarcoidosis=136
HP=33,
sarcoidosis=50,
IPF=37, CTDILD=23, other
interstitial
pneumonitis=18,
undefined form of
fibrosis=19
HP=10,
sarcoidosis=83,
control=15

atients included in this study met the following criteria: (1)
history of exposure to antigens known to produce
hypersensitivity pneumonitis within 30 days of the date of
evaluation; (2) symptoms, clinical signs, and abnormalities on
chest radiographs or results of pulmonary function tests
compatible with hypersensitivity pneumonitis, or both, and
the absence of signs, symptoms, and findings from pulmonary
function testing (when available) compatible with a diagnosis
of asthma; (3) no history of corticosteroid administration for at
least one year before the onset of the present illness; (4)
presence of serum antibodies against the relevant antigen as
determined by immunoeletrophoresis or immunodiffusion or
both; (5) prompt improvement in symptoms, chest
radiographs, or pulmonary function test results when further
antigen exposure was prevented or, in some cases, when
corticosteroid (0 5 mg prednisone/kg body weight/day) was
administered; (6) the date of last antigen exposure before
evaluation known; (7) availability of bronchoalveolar lavage
data. Th
Subacute and chronic HP diagnosis criteria included BAL.
Possible and Definite chronic EAA included BAL lymphocytosis.
Probable did not. Patients were divided by age group: < 30, 3060 and > 60. However, BAL results are note stratified by
subacute vs. Chronic. They are stratified by age.

Not specified.

Exposure to an agent that can induce hypersensitivity
pneumonitis, shortness of breath with partial clinical and
functional improvement upon avoidance of the offending
agent, a restrictive lung function pattern, the presence of
ground glass and/or fibrosis pattern on high-resolution
computed tomography and the presence of a lymphocytosis in
the BALF. If clinical, BAL and radiological features were not
convincing, a lung biopsy or a specific challenge test was
performed to strengthen the diagnosis of HP.
Criteria Schuyler. Symptoms compatible with HP, serologic
evidence or history of antigen exposure, CXR or HRCT findings
compatible with HP, lymphocytosis in the BAL, compatible
histologic findings on lung biopsy and reproduction of
symptoms after exposure to the antigenic environment. Mino
criteria are bibasilar rales, decreased diffusing capacity and
arterial hypoxemia.

Not specified.

BAL

cell count
and
differential

Serious risk of bias
due to nonconsecutive
enrollment

Mixed.

BAL

cell count
and
differential
Serious risk of bias
due to nonconsecutive
enrollment

Not specified.
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BAL

cell count
and
differential

cell count
and
differential

Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
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Welker
2004

NRS

Germany

Wojtan
2016

NRS

Poland

Zissel
2000

NRS

Germany

HP=66,
sarcoidosis= 239,
IPF=112, iNSIP=46,
COP= 17
HP=10,
sarcoidosis=36,
IPF=6, NSIP=8,
other ILD=15
HP=9, active
sarcoidosis=15,
inactive
sarcoidosis=15,
cryptogenic
fibrosing
alveolitis=11,
TB=9,
pneumonia=8,
control=23

Clinically and/or histologically established final diagnosis was
available in all patients

Not specified.

BAL

cell count
and
differential

Diagnoses were stablished in accordance with proper
guidelines.

Not specified.

BAL

cell count
and
differential

not specified

Not specified.
Farmer's
lung=5, pigeon
breeder=2,
parakeet
keeper=2.

BAL

cell count
and
differential
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Serious risk of bias
due to nonconsecutive
enrollment
Serious risk of bias
due to nonconsecutive
enrollment

Serious risk of bias
due to nonconsecutive
enrollment
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Figure E1. Funnel plots to detect publication bias. The circles indicate included studies, y-axis indicates standard error, x-axis
indicates the effect, and the dashed vertical line identifies the summary effect. The precision of an estimated effect increases as the
size of the study increases. Therefore, effect estimates from small studies will typically scatter more widely at the bottom of the graph,
with the spread narrowing among larger studies, resulting in a plot that resembles a symmetrical (inverted) funnel. Asymmetry is
suggestive of possible publication bias.
A) Fibrotic HP versus IPF

C) Fibrotic HP versus sarcoidosis

B) Non-fibrotic HP versus IPF

D) Non-fibrotic HP versus sarcoidosis
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